• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Akero Therapeutics' Phase 2b SYMMETRY Cohort D Study Met Safety & Tolerability Endpoints and Showed Adding EFX to GLP-1 Therapy Significantly Improved Non-Invasive Markers of NASH-Related Disease

    6/5/23 7:00:00 AM ET
    $AKRO
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $AKRO alert in real time by email

    Patients treated with EFX for 12 weeks combined with GLP-1 achieved a 65% relative reduction in liver fat, compared to a 10% relative reduction for GLP-1 alone

    88% of patients treated with EFX combined with GLP-1 had normalized liver fat at week 12, compared with 10% of those treated with GLP-1 alone

    EFX-treated patients also experienced statistically significant improvements in liver enzymes and noninvasive markers of fibrosis, glycemic control, and lipids

    Investor webcast at 8:00 am ET today to further discuss data

    SOUTH SAN FRANCISCO, Calif., June 05, 2023 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (NASDAQ:AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic disease marked by high unmet medical need, today released topline data from an expansion cohort (N=31) of the Phase 2b SYMMETRY study known as Cohort D. The primary aim of the 12-week study was to assess safety and tolerability of Akero's lead product candidate, efruxifermin (EFX), compared to placebo when added to an existing GLP-1 receptor agonist (GLP-1) in patients with Type 2 diabetes (T2D) and F1-F3 liver fibrosis due to non-alcoholic steatohepatitis (NASH).

    EFX was reported to be generally well tolerated in Cohort D with comparable results for the EFX (N=21) and placebo (N=10) groups. The overall tolerability profile was similar to that observed in Akero's BALANCED and HARMONY studies. The most frequent adverse events for EFX-treated patients were grade 1 or 2 gastrointestinal events (diarrhea, nausea, and increased appetite). One patient treated with EFX discontinued due to nausea and one EFX-treated patient discontinued after withdrawing consent. There were no drug-related serious adverse events.

    Cohort D also met all key secondary endpoints, including relative reduction of liver fat and proportion of patients whose absolute liver fat level normalized to 5 percent or less. We believe these data, together with statistically significant improvements across many other key NASH-related measures, show that EFX could be an important treatment for patients with NASH who are being treated with GLP-1 for T2D or obesity.

    "A substantial portion of patients who have NASH are obese and have Type 2 diabetes, with utilization of GLP-1 therapies increasing rapidly to treat these underlying comorbidities", said Stephen Harrison, M.D., chairman and founder of Pinnacle Clinical Research and principal investigator for the SYMMETRY study. "With this in mind, it is highly encouraging that the Cohort D results not only showed that EFX combined with GLP-1 appeared to be adequately tolerated, but also the combination offered substantial benefit over GLP-1 therapy alone based on multiple key NASH endpoints. Hepatic steatosis was still present in patients on GLP-1 therapy, approximately two-thirds of whom were treated with GLP-1 for over one year, and 88% of patients resolved hepatic steatosis completely when EFX was added."

    "We're highly encouraged by the strength and consistency of results across our Phase 2 studies to date," said Kitty Yale, chief development officer of Akero. "With the added support of this newest data set, we believe EFX has the potential to play an important role in treating patients with NASH who are receiving GLP-1 therapy in addition to the potential to be a foundational monotherapy for patients with NASH. We look forward to initiating two Phase 3 SYNCHRONY studies later this year to further our goal of addressing high unmet need across the globe for patients living with NASH."

    Summary of Week 12 Changes in Liver Fat

    Measure Placebo

    (N=10)
    EFX 50mg

    (N=16)
    Hepatic Fat Fraction (MRI-PDFF) (%), LS Mean Relative Change from Baseline-10-65 ***
    Proportion of patients achieving ≥50% Relative Reduction in Liver Fat (%)088 ***
    Proportion of patients with Normalized (≤5%) Liver Fat (%)1088***

    *** p<0.001, versus placebo (ANCOVA)

    Summary of Key Markers of Fibrosis and Liver Injury, LS Mean Absolute Change from Baseline to Week 12

    Measure Placebo

    (N=10)
    EFX 50mg

    (N=21)
    Pro-C3 (µg/L)-2.7-5.2 ††
    ELF Score+0.1-0.6 **
    Liver Stiffness (kPa) (FibroScan)-1.1-3.0 †††
    FAST Score+0.04-0.16 ***
    ALT (U/L)-1.0-10 *
    AST (U/L)+1.5-5.3 *

    * p<0.05, ** p<0.01, *** p<0.001, versus placebo (Mixed Model Repeated Measures [MMRM])

    †† p<0.01, ††† p<0.001, versus baseline (MMRM)

    Summary of Key Cardio-Metabolic Biomarkers, LS Mean Relative Change from Baseline to Week 12

    Measure Placebo

    (N=10)
    EFX 50mg

    (N=21)
    HbA1c (%, absolute)-0.2-0.5 †††
    Insulin (%)-13-26
    C-Peptide (%)-3.5-22 †
    Adiponectin (%)+16+129 ***
    Triglycerides (%)-4.1-42 ***
    Non-HDL Cholesterol (%)-6.8-19 †††
    Apolipoprotein B (%)-4.5-21 *
    LDL Cholesterol (%)-6.1-8.0
    HDL Cholesterol (%)+2.5+38 ***
    Body Weight (kg)-0.8-1.2

    ** p<0.01, *** p<0.001, versus placebo (MMRM)

    † p<0.05, ††† p<0.001, versus baseline (MMRM)

    In July of 2021, Akero initiated the SYMMETRY main study, a Phase 2b trial in biopsy-confirmed NASH patients with compensated cirrhosis (F4), Child-Pugh class A. Akero expects to report results from the ongoing study in the fourth quarter of 2023.

    Conference Call / Webcast Details

    Akero will host a conference call and webcast with slide presentation at 8:00 a.m. ET today. The live webcast will be available on the Events & Presentations page of the Akero website, with the recording and presentation available immediately following the event.

    About NASH

    NASH is a serious form of NAFLD (non-alcoholic fatty liver disease) that is estimated to affect 17 million Americans. NASH is characterized by an excessive accumulation of fat in the liver that causes stress and injury to liver cells, leading to inflammation and fibrosis, which can progress to cirrhosis, liver failure, cancer and eventually death. There are no approved treatments for the condition and NASH is the fastest growing cause of liver transplants and liver cancer in the US and Europe.

    About Efruxifermin

    Efruxifermin (EFX), formerly known as AKR-001, is Akero's lead product candidate for NASH, currently being evaluated in the ongoing Phase 2b HARMONY and SYMMETRY studies. EFX is designed to reduce liver fat and inflammation, reverse fibrosis, increase insulin sensitivity and improve lipids. This holistic approach offers the potential to address the complex, multi-system disease state of NASH, including improvements in lipoprotein risk factors linked to cardiovascular disease – the leading cause of death in NASH patients. Engineered to mimic the biological activity profile of native FGF21, EFX is designed to offer convenient once-weekly dosing and has been generally well-tolerated in clinical trials to date.

    About Akero Therapeutics

    Akero Therapeutics is a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, including NASH, a disease without any approved therapies. Akero's lead product candidate, EFX, is a differentiated Fc-FGF21 fusion protein that has been engineered to mimic the balanced biological activity profile of native FGF21, an endogenous hormone that alleviates cellular stress and regulates metabolism throughout the body. EFX is designed to offer convenient once-weekly subcutaneous dosing. The consistency and magnitude of observed effects position EFX to be a potentially best-in-class medicine, if approved, for treatment of NASH. EFX is currently being evaluated in two Phase 2b clinical trials: the HARMONY study in patients with pre-cirrhotic NASH (F2-F3 fibrosis), and the SYMMETRY study in patients with cirrhotic NASH (F4 fibrosis, compensated). EFX is also being evaluated in an expansion cohort of the SYMMETRY study, comparing the safety and tolerability of EFX to placebo when added to an existing GLP-1 receptor agonist in patients with pre-cirrhotic NASH (F1-F3 fibrosis) and Type 2 diabetes. Akero is headquartered in South San Francisco. Visit us at akerotx.com and follow us on LinkedIn and Twitter for more information.

    Forward Looking Statements

    Statements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements, including, but not limited to, statements regarding Akero's business plans and objectives, including future plans or expectations for EFX, the therapeutic effects of EFX, as well as the dosing, safety and tolerability of EFX, including in combination with GLP-1 therapies; and upcoming milestones, including the results, and expected timing to report such results of Akero's Phase 2b SYMMETRY study. Any forward-looking statements in this press release are based on management's current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. Risks that contribute to the uncertain nature of the forward-looking statements include: the success, cost, and timing of Akero's product candidate development activities and planned clinical trials; Akero's ability to execute on its strategy; positive results from a clinical study, including Cohort D, may not necessarily be predictive of the results of future or ongoing clinical studies; regulatory developments in the United States and foreign countries; Akero's ability to fund operations; as well as those risks and uncertainties set forth more fully under the caption "Risk Factors" in Akero's most recent Annual Report on Form 10-K and Quarterly Report on Form 10-Q, as filed with the Securities and Exchange Commission (SEC) as well as discussions of potential risks, uncertainties and other important factors in Akero's other filings and reports with the SEC. All forward-looking statements contained in this press release speak only as of the date on which they were made. Akero undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.

    Investor Contact:

    Christina Tartaglia

    212.362.1200

    [email protected]

    Media Contact:

    Sarah O'Connell

    732.456.0092

    [email protected]



    Primary Logo

    Get the next $AKRO alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $AKRO

    DatePrice TargetRatingAnalyst
    1/30/2025$35.00 → $63.00Neutral → Buy
    BofA Securities
    1/27/2025$50.00 → $72.00Buy
    H.C. Wainwright
    11/18/2024$65.00Buy
    Citigroup
    4/22/2024$30.00Neutral
    BofA Securities
    9/19/2023$69.00Overweight
    Cantor Fitzgerald
    8/28/2023$83.00Buy
    UBS
    1/27/2023$40.00 → $65.00Equal-Weight → Overweight
    Morgan Stanley
    9/14/2022$10.00 → $50.00In-line → Outperform
    Evercore ISI
    More analyst ratings

    $AKRO
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Akero Therapeutics to Present at the Jefferies Global Healthcare Conference

      SOUTH SAN FRANCISCO, Calif., May 28, 2025 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (NASDAQ:AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, today announced that management will present at the Jefferies Global Healthcare Conference on Wednesday, June 4, 2025, at 8:45 a.m. P.T. A live webcast of the Company presentation will be available through the investor relations section of the Company's website at www.akerotx.com. Following the live webcast, an archived replay will be available on the Company's website. About Akero TherapeuticsAkero Therapeutics is a clinical-stage company develo

      5/28/25 7:00:00 AM ET
      $AKRO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Akero Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update

      Phase 2b SYMMETRY study preliminary results showed statistically significant reversal of compensated cirrhosis (F4) due to MASH following 96 weeks of treatment with efruxifermin (EFX) Presented two oral presentations and a poster presentation highlighting the latest data and new analyses from 96-week SYMMETRY and HARMONY clinical studies at EASL Congress 2025 SYMMETRY study results published in New England Journal of Medicine Raised $402.5 million in gross proceeds in a follow-on public offering in January 2025, resulting in reserves of cash, cash equivalents, and marketable securities of $1,128 million at March 31, 2025 SOUTH SAN FRANCISCO, Calif., May 12, 2025 (GLOBE NEWSWIRE) -- Ak

      5/12/25 7:00:00 AM ET
      $AKRO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Akero Therapeutics and HistoIndex Present New Analyses of Phase 2b HARMONY Trial in Oral and Poster Presentations at the EASL Congress 2025

      Analysis of EFX results with AI-based digital pathology underscores the potential value in evaluating histopathology response Data contribute to growing body of support around the anti-fibrotic activity of EFX in patients with pre-cirrhotic MASH SOUTH SAN FRANCISCO, Calif., May 10, 2025 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (NASDAQ:AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, today announced results from new analyses of the 96-week Phase 2b HARMONY trial of efruxifermin (EFX) in patients with pre-cirrhotic (F2-F3 fibrosis) metabolic dysfunction-associated steatohepatitis (MASH

      5/10/25 10:00:00 AM ET
      $AKRO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AKRO
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Graham G. Walmsley bought $8,787,921 worth of shares (200,000 units at $43.94) (SEC Form 4)

      4 - Akero Therapeutics, Inc. (0001744659) (Issuer)

      3/27/25 7:42:13 PM ET
      $AKRO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Graham G. Walmsley bought $9,600,000 worth of shares (200,000 units at $48.00) (SEC Form 4)

      4 - Akero Therapeutics, Inc. (0001744659) (Issuer)

      2/7/25 7:54:28 PM ET
      $AKRO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Graham G. Walmsley bought $1,982,940 worth of shares (100,000 units at $19.83) (SEC Form 4)

      4 - Akero Therapeutics, Inc. (0001744659) (Issuer)

      12/11/23 9:06:30 PM ET
      $AKRO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AKRO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Senior VP, Commercial Strategy Lamy Patrick exercised 4,000 shares at a strike of $44.37 and sold $200,000 worth of shares (4,000 units at $50.00) (SEC Form 4)

      4 - Akero Therapeutics, Inc. (0001744659) (Issuer)

      5/23/25 5:30:04 PM ET
      $AKRO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Development Officer Yale Catriona exercised 10,000 shares at a strike of $21.10 and sold $392,978 worth of shares (10,000 units at $39.30) (SEC Form 4)

      4 - Akero Therapeutics, Inc. (0001744659) (Issuer)

      5/19/25 7:06:47 PM ET
      $AKRO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • President and CEO Cheng Andrew sold $1,244,455 worth of shares (30,000 units at $41.48), decreasing direct ownership by 5% to 594,324 units (SEC Form 4)

      4 - Akero Therapeutics, Inc. (0001744659) (Issuer)

      5/13/25 9:11:49 PM ET
      $AKRO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AKRO
    Financials

    Live finance-specific insights

    See more
    • Akero Therapeutics Reports Preliminary Topline Results Showing Statistically Significant Reversal of Compensated Cirrhosis (F4) Due to MASH—by Both Completer and ITT Analyses—at Week 96 in Phase 2b SYMMETRY Study

      Among patients with baseline and week 96 biopsies, 39% of the 50mg EFX group (p=0.009) demonstrated ≥1 stage improvement in fibrosis with no worsening of MASH, representing a 24% effect size over placebo at 15% By ITT analysis, with all missing week 96 biopsies treated as failures, 29% of the 50mg EFX group (p=0.031) demonstrated ≥1 stage improvement in fibrosis with no worsening of MASH, representing a 17% effect size over placebo at 12% Investor webcast at 8:00 am ET Monday, January 27, 2025 SOUTH SAN FRANCISCO, Calif., Jan. 27, 2025 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (NASDAQ:AKRO), a clinical-stage company developing transformational treatments for patients with serious me

      1/27/25 6:30:00 AM ET
      $AKRO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Akero Therapeutics to Present Preliminary Topline Week 96 Results from Phase 2b SYMMETRY Study Investigating Efruxifermin in Patients with Compensated Cirrhosis (F4) Due to MASH

      Investor webcast on Monday, January 27, 2025, at 8:00 a.m. ET to present clinical data SOUTH SAN FRANCISCO, Calif., Jan. 24, 2025 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (NASDAQ:AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic disease marked by high unmet medical need, will hold an investor conference on Monday, January 27, 2025, at 8:00 a.m. ET to share preliminary topline week 96 results from its SYMMETRY study, a double-blind, placebo-controlled Phase 2b study evaluating the efficacy of efruxifermin (EFX) in patients with compensated cirrhosis (F4) due to metabolic dysfunction-associated steatohepatitis (MASH). Conferenc

      1/24/25 4:05:00 PM ET
      $AKRO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Akero Therapeutics Reports Statistically Significant Histological Improvements at Week 96 in Phase 2b HARMONY Study

            50mg (75%, p<0.001) and 28mg (46%, p=0.07) EFX groups demonstrated ≥1 stage improvement in fibrosis without worsening of MASH, approximately three- and two-fold the placebo rate (24%) 50mg (36%, p<0.01) and 28mg (31%, p<0.01) EFX groups demonstrated ≥2 stage improvement in fibrosis without worsening of MASH, more than 10-fold the placebo rate (3%) EFX-treated patients experienced statistically significant improvements on nearly all histological endpoints by ITT analysis as well as the primary analysis of patients with week 96 biopsies Investor webcast at 8:00 am ET Monday, March 4, 2024 SOUTH SAN FRANCISCO, Calif., March 04, 2024 (GLOBE NEWSWIRE) --  Akero Therapeutics,

      3/4/24 6:00:00 AM ET
      $AKRO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AKRO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Akero Therapeutics Inc.

      SC 13G/A - Akero Therapeutics, Inc. (0001744659) (Subject)

      11/14/24 3:59:41 PM ET
      $AKRO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Akero Therapeutics Inc.

      SC 13G/A - Akero Therapeutics, Inc. (0001744659) (Subject)

      11/14/24 1:22:38 PM ET
      $AKRO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Akero Therapeutics Inc.

      SC 13G/A - Akero Therapeutics, Inc. (0001744659) (Subject)

      11/14/24 6:51:23 AM ET
      $AKRO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AKRO
    SEC Filings

    See more
    • Amendment: SEC Form SCHEDULE 13G/A filed by Akero Therapeutics Inc.

      SCHEDULE 13G/A - Akero Therapeutics, Inc. (0001744659) (Subject)

      5/15/25 8:13:34 AM ET
      $AKRO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SCHEDULE 13G/A filed by Akero Therapeutics Inc.

      SCHEDULE 13G/A - Akero Therapeutics, Inc. (0001744659) (Subject)

      5/14/25 12:24:45 PM ET
      $AKRO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 144 filed by Akero Therapeutics Inc.

      144 - Akero Therapeutics, Inc. (0001744659) (Subject)

      5/12/25 6:47:52 PM ET
      $AKRO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AKRO
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Akero Therapeutics upgraded by BofA Securities with a new price target

      BofA Securities upgraded Akero Therapeutics from Neutral to Buy and set a new price target of $63.00 from $35.00 previously

      1/30/25 7:09:02 AM ET
      $AKRO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • H.C. Wainwright reiterated coverage on Akero Therapeutics with a new price target

      H.C. Wainwright reiterated coverage of Akero Therapeutics with a rating of Buy and set a new price target of $72.00 from $50.00 previously

      1/27/25 11:47:01 AM ET
      $AKRO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Citigroup initiated coverage on Akero Therapeutics with a new price target

      Citigroup initiated coverage of Akero Therapeutics with a rating of Buy and set a new price target of $65.00

      11/18/24 7:26:08 AM ET
      $AKRO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AKRO
    Leadership Updates

    Live Leadership Updates

    See more
    • Akero Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update

      -- Initiated Phase 3 SYNCHRONY Outcomes Trial of Lead Candidate Efruxifermin (EFX) in Patients with Compensated Cirrhosis (F4) Due to MASH -- Presented Poster and Late-breaking Oral Presentation on EFX at the EASL Congress 2024 -- -- Leadership Team Expanded with Addition of Scott Gangloff as Chief Technical Officer -- SOUTH SAN FRANCISCO, Calif., Aug. 09, 2024 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (NASDAQ:AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, today reported second quarter financial results for the period ending June 30, 2024 and provided business updates. "The second

      8/9/24 7:00:00 AM ET
      $AKRO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Akero Therapeutics Appoints Scott Gangloff as Chief Technology Officer

      SOUTH SAN FRANCISCO, Calif., April 30, 2024 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (NASDAQ:AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic disease, today announced the appointment of Scott Gangloff as Chief Technology Officer. "I am delighted to welcome Scott to Akero. His depth of experience leading drug manufacturing for both national and multi-national biopharmaceutical organizations enriches our company with an invaluable perspective during the late-stage clinical development of efruxifermin," remarked Andrew Cheng, M.D., Ph.D., president and chief executive officer of Akero. "The entire leadership team looks forward to

      4/30/24 8:00:00 AM ET
      $AKRO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Akero Therapeutics Appoints Patrick Lamy as Senior Vice President, Commercial Strategy

      SOUTH SAN FRANCISCO, Calif., Jan. 10, 2023 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (NASDAQ:AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic disease marked by high unmet medical need, today announced the appointment of Patrick Lamy as Senior Vice President, Commercial Strategy. "Akero is thrilled to welcome Patrick to the team, especially following last year's HARMONY study results, which further demonstrate EFX's potential to treat NASH holistically and reverse fibrosis rapidly," said Andrew Cheng, M.D., Ph.D., president and chief executive officer of Akero. "Patrick's extensive experience in liver disease, and commercial stra

      1/10/23 8:00:00 AM ET
      $AKRO
      Biotechnology: Pharmaceutical Preparations
      Health Care